Equities

Nanovibronix Inc

Nanovibronix Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.69
  • Today's Change-0.021 / -2.94%
  • Shares traded15.84k
  • 1 Year change-73.46%
  • Beta1.4969
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NanoVibronix, Inc. is a medical device company. The Company develops medical devices utilizing its patented low intensity surface acoustic wave technology. Its products include UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use. UroShield Ultra is similar to UroShield, but is designed to prevent bacterial colonization and biofilm formation in urinary catheters. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD, PainShield Plus and WoundShield. WoundShield is a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.

  • Revenue in USD (TTM)3.37m
  • Net income in USD-2.82m
  • Incorporated2003
  • Employees10.00
  • Location
    Nanovibronix Inc525 Executive BlvdELMSFORD 10523United StatesUSA
  • Phone+1 (914) 233-3004
  • Websitehttps://nanovibronix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nemaura Medical Inc0.00-10.65m1.17m36.00---------0.3787-0.37870.00-0.61690.000.00--0.00-117.49-58.18---131.96-------7,384.830.0305-1.4710.81---84.71---1.85--64.14--
Catheter Precision Inc436.00k-9.49m1.26m14.00--0.0238--2.89-12.95-12.950.604618.900.01410.55743.8931,142.86-30.71---33.63--92.20---2,176.84--0.098--0.0434--3,057.14---165.67------
Hawkeye Systems Inc0.00-804.18k1.58m44.00---------0.1186-0.11860.00-0.290.00-------66.07-330.11-----------218.49---2.7810.45------4.85------
Tivic Health Systems Inc1.11m-6.75m1.67m9.00--0.3978--1.50-4.33-4.330.54690.67790.23730.915676.76123,666.70-143.94---176.98--27.85---606.47--6.59--0.00---36.09--18.34------
NanoVibronix Inc3.37m-2.82m1.92m10.00--0.6762--0.5696-1.32-1.321.501.020.70810.43112.05337,300.00-59.12-116.16-122.41-169.3664.5750.47-83.49-570.471.16-14.770.00--203.5948.3331.88---34.02--
BIOLASE Inc46.10m-36.19m2.01m157.00------0.0437-11.65-11.653.32-0.06361.312.558.73293,611.50-54.64-49.28-185.36-85.8033.0135.27-41.65-50.720.3589-6.001.19--1.451.27-30.39--18.63--
Avinger Inc7.43m-15.34m2.19m68.00--0.2361--0.2952-12.13-12.135.834.050.4341.238.03109,250.00-113.20-70.93-1,387.68-131.5719.9630.87-260.86-208.911.20-11.660.3428---7.51-0.673632.76---24.21--
Arch Therapeutics Inc148.17k-12.99m2.27m8.00------15.30-3.69-3.690.0383-2.830.100.0662--18,521.25-828.03-188.28---804.6339.58---8,276.08-26,945.920.0051-1.32----383.83---32.35---21.76--
Nuwellis Inc9.01m-22.81m2.35m59.00------0.261-181.60-181.6048.48-13.250.82921.527.30152,779.70-192.57-98.07-301.19-122.4860.2855.22-232.24-230.510.7119-1.52----3.7612.14-55.78--4.61--
Optimus Healthcare Services Inc1.89m-7.16m2.46m12.00------1.30-0.1744-0.17440.0454-0.18891.26--3.67157,291.70-477.28------85.93---379.51-----5.42----22.88---3.51------
Sonendo Inc37.46m-47.49m2.50m216.00--0.14--0.0668-0.5017-0.44360.39520.24530.4981.956.91173,421.30-63.14---78.26--35.04---126.79--1.73-8.540.5194--5.30---6.78------
Vycor Medical Inc1.36m-506.30k2.58m8.00------1.90-0.0155-0.01560.0417-0.10811.430.66945.08170,011.30-19.13-47.86----89.2389.60-13.38-35.420.0987-0.8001----19.43-0.654246.49---31.77--
SINTX Technologies Inc3.13m-8.60m2.59m43.00--0.2927--0.8271-271.52-271.5216.4411.820.18181.777.6372,697.67-50.01-45.71-62.67-57.3667.7258.47-275.14-681.801.79--0.0265--68.2994.2449.75--54.10--
Helius Medical Technologies Inc594.00k-8.84m2.61m22.00--0.4116--4.39-10.68-10.680.50421.980.06060.74864.4827,000.00-90.17-98.37-110.33-143.5712.7937.27-1,487.54-1,580.663.80--0.00---18.176.1437.11---41.95--
Invo Bioscience Inc5.77m-7.08m2.72m25.00------0.4706-3.24-3.242.440.35290.467712.0034.74230,781.20-57.44-94.63-116.03-151.4544.8974.91-122.80-343.110.2686-4.750.6588--267.3843.6226.24--87.09--
Data as of Sep 20 2024. Currency figures normalised to Nanovibronix Inc's reporting currency: US Dollar USD

Institutional shareholders

8.38%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 30 Jun 2024136.89k4.92%
The Vanguard Group, Inc.as of 30 Jun 202430.19k1.08%
Geode Capital Management LLCas of 30 Jun 202423.13k0.83%
Renaissance Technologies LLCas of 30 Jun 202421.55k0.77%
Citadel Securities LLCas of 30 Jun 202415.35k0.55%
Tower Research Capital LLCas of 30 Jun 20246.07k0.22%
UBS Securities LLCas of 30 Jun 202446.000.00%
Bank of America, NA (Private Banking)as of 30 Jun 202417.000.00%
Wells Fargo Bank, NA (Private Banking)as of 30 Jun 20240.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.